Spectral AI, Inc. logo
Nasdaq: MDAI · active
AI products
PROBABLE

Spectral AI, Inc.

A medical-diagnostic developer whose DeepView system uses AI for burn assessment.

AI productsHealthcare & drug discoveryOfficial website

Research candidate, not an investment rating. Identity and classification reflect a bounded evidence snapshot observed Jul 26, 2026.

VCAI-RC-0012-EXP-01
External market projection

MDAI market context

Close Aug 4, 2026 · Yahoo Finance chart endpoint
$1.65
Latest close
+2.48%
1 day
-7.82%
30 days
-30.96%
1 year
$2.97
52w high
$1.18
52w low
External end-of-day market projection. It is not canonical company knowledge and may be delayed or corrected by the provider.Source projection
Regulator-sourced financials

SEC financial snapshot

CIK 0001833498 · Surgical & Medical Instruments & Apparatus
Latest quarter · 10-Q

Period ended Mar 31, 2026 · filed May 13, 2026

Open filing
$4M
Revenue
$2M
Gross profit
$-2M
Operating income
$-3.4M
Net income
Latest annual · 10-K

Period ended Dec 31, 2025 · filed Mar 25, 2026

Open filing
$19.7M
Revenue
$8.9M
Gross profit
$-8.6M
Operating income
$-7.6M
Net income

Values are issuer-filed XBRL facts retrieved from SEC EDGAR. Missing concepts remain Unknown; non-GAAP values are not substituted.

Explainable company intelligence

What makes this an AI company—and what changed recently.

AI roles are presented as source-anchored research interpretations. The document stream is regulator-primary, but a filing’s existence does not prove the claims contained inside it.

AI Exposure Ledger

Role evidence, not a proprietary investment score

1 dimensions

AI products

Primary classified role
REAL-011-EXP-01

AI is a material capability inside one or more current products or services.

Evidence basis

The annual filing identifies Spectral AI, its MDAI listing and AI-based medical-diagnostic development.

Anchors: SRC-REAL-011-A · SRC-REAL-011-B

Why it is in the map

01

The annual filing identifies Spectral AI, its MDAI listing and AI-based medical-diagnostic development.

02

The issuer reports FDA De Novo clearance permitting U.S. commercial distribution of DeepView for its burn indication.

Evidence chain

These sources support the issuer/listing and AI-exposure assessment. First-party evidence proves attribution—not independent truth.

Official filing or report · E3
Spectral AI 2024 Form 10-K
SRC-REAL-011-A
Official product evidence · E3
DeepView FDA De Novo Clearance
SRC-REAL-011-B

What would trigger a review

  • First material commercial-distribution or revenue evidence.
  • Regulatory status or product indication change.
  • New annual report, listing or issuer change.